Observational studyScientific reports2026
Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Immunological Intersection of Psoriasis and Autoimmune Diseases: Shared Pathways and Clinical Implications.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
74 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Real-world evidence on 12-month outcomes of guselkumab (GUS) in psoriatic arthritis (PsA) remains limited. This multicenter observational study aimed to identify predictors of 12-month DAPSA remission (DAPSA < 4) in patients with PsA treated with GUS. Secondary objectives were to assess remission rates and changes in disease activity at 6 and 12 months. We screened all patients with PsA initiating GUS across 26 Italian rheumatology centers. Data collected included demographics, disease activity measured by DAPSA, and psoriasis (PsO) extent classified as 0%, < 10%, 10-20%, or > 20% body surface area. A multivariable logistic regression model restricted to patients with an evaluable 6-month assessment was used to identify predictors of 12-month DAPSA remission. Covariates included age, sex, smoking status, body mass index, disease duration, number of prior advanced therapies, axial involvement, and 6-month articular and/or cutaneous response. Articular response was defined as DAPSA remission (DAPSA < 4), and cutaneous response as improvement by at least one PsO body surface area severity category. A two-sided p value < 0.05 was considered statistically significant. Of 278 initiators, 199 were evaluable at 6 months. At month 6, 18 patients had a combined articular and cutaneous response, 9 had an articular-only response, 74 had a cutaneous-only response, and 98 had no response. In intention-to-treat analyses, DAPSA remission was achieved by 12% at 6 months and 20% at 12 months; corresponding per-protocol rates were 16% and 30%. Median DAPSA decreased from 27.0 at baseline to 11.9 at 6 months and 8.6 at 12 months. In multivariable analysis, combined response (OR 64.6, 95% CI 5.7-731.2), joint-only response (OR 16.9, 95% CI 4.4-65.2), and skin-only response (OR 2.5, 95% CI 1.04-6.2) were associated with 12-month DAPSA remission. In routine practice, 6-month response status stratified the probability of 12-month DAPSA remission. Early articular remission and combined articular-cutaneous response showed the strongest associations, whereas skin-only improvement was a modest but statistically significant predictor and should not be interpreted as a strong determinant of later articular remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.